


Avanafil

Cat. No.:	HY-18252
CAS No.:	330784-47-9
Molecular Formula:	C ₂₃ H ₂₆ ClN ₇ O ₃
Molecular Weight:	483.95
Target:	Phosphodiesterase (PDE); NO Synthase; Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease; Immunology/Inflammation
Storage:	<div> <div>Powder</div> <div>-20°C 3 years</div> <div>4°C 2 years</div> </div> <div> <div>In solvent</div> <div>-80°C 2 years</div> <div>-20°C 1 year</div> </div>



SOLVENT & SOLUBILITY

In Vitro	DMSO : 14.29 mg/mL (29.53 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.0663 mL	10.3316 mL	20.6633 mL
		5 mM		0.4133 mL	2.0663 mL	4.1327 mL
		10 mM		0.2066 mL	1.0332 mL	2.0663 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC ₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis ^{[1][2][3]} .			
IC ₅₀ & Target	PDE5	PDE6	PDE4	PDE10

	5.2 nM (IC ₅₀)	630 nM (IC ₅₀)	5700 nM (IC ₅₀)	6200 nM (IC ₅₀)
	PDE7 27000 nM (IC ₅₀)	PDE2 51000 nM (IC ₅₀)	PDE1 53000 nM (IC ₅₀)	
In Vitro	Avanafil (TA-1790) (0.01-1000 μM) enhances by 45% for electrical field stimulation (1-20 Hz)-induced relaxation responses in corpus cavernosum strips from the diabetic group ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	Avanafil (TA-1790) (10 mg/kg; p.o.; daily, for 30 d; male rat) increases angiogenesis in bone tissue via the activation of NO, cGMP and PKG (NO/cGMP/PKG) signaling-pathway and significantly decreases dexamethasone-induced loss in BMD, bone atrophy, and oxidative stress ^[1] . Avanafil (TA-1790) (10 μM; ICI; once, for 10 weeks) improves erectile responses in T2DM rats ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Male rat model of glucocorticoid-induced osteoporosis (GIOP) ^[1]		
	Dosage:	10 mg/kg		
	Administration:	Oral administration; daily, for 30 days		
	Result:	Decreased the level of eNOS, NO, PDE-5, PICP, MDA, CoQ10/CoQ10H and 8-OHdG/10 ⁸ dG. Increased the level of cGMP, PKG, Cortisol and CTCP.		
	Animal Model:	Male rat model of glucocorticoid-induced osteoporosis (GIOP) ^[1]		
	Dosage:	10 mg/kg		
	Administration:	Oral administration; daily, for 30 days		
	Result:	Increased right femur trabecular bone thickness and epiphyseal bone width.		
	Animal Model:	Male T2DM Sprague Dawley rats ^[2]		
	Dosage:	10 μM		
	Administration:	Intracavernous injection; once, for 10 weeks		
	Result:	Increased in ICP/MAP in response to nerve stimulation and increased total ICP values.		

CUSTOMER VALIDATION

- Chemrxiv. 2021, Jun 10.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Huyut Z, et, al. Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. Med Sci Monit Basic Res. 2018 Mar 13;24:47-58.

[2]. Yilmaz D, et, al. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. 2014 Feb;83(2):508.e7-12.

[3]. Kotera J, et, al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA